Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 6/2013

01-06-2013 | Original Research Paper

Association of interleukin-1 receptor-associated kinase (IRAK1) gene polymorphisms (rs3027898, rs1059702) with systemic lupus erythematosus in a Chinese Han population

Authors: Yu Zhai, Ke Xu, Rui-Xue Leng, Han Cen, Wei Wang, Yan Zhu, Mo Zhou, Chen-Chen Feng, Dong-Qing Ye

Published in: Inflammation Research | Issue 6/2013

Login to get access

Abstract

Objective

The purpose of this study was to examine the association of interleukin-1 receptor-associated kinase (IRAK1) polymorphisms (rs3027898, rs1059702) with systemic lupus erythematosus (SLE) in a Chinese Han population.

Methods

A total of 667 SLE patients and 667 healthy controls were collected in this study. The genotyping of polymorphisms (rs3027898, rs1059702) was determined by TaqMan allele discrimination assay on the 7300 real-time polymerase chain reaction system. The statistical analysis was conducted by chi square test or Fisher’s exact test.

Results

The frequency of C allele for rs3027898 in patients was significantly higher than in controls (C versus A: OR = 1.438, 95 % CI = 1.180–1.753, p < 0.001), and a similar association was shown in rs1059702 (A versus G: OR = 1.383, 95 % CI = 1.143–1.674, p = 0.001). Interestingly, the C allele of rs3027898 was associated with a decreased risk for patients with oral ulcers. However, no significant difference was detected in IRAK1 rs1059702 polymorphism and the clinical manifestations.

Conclusions

Our data demonstrate that the polymorphisms rs3027898 and rs1059702 of IRAK1 gene are associated with SLE in the Chinese Han population.
Literature
1.
Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features and mortality. Arthritis Care Res (Hoboken). 2012;64:159–68.CrossRef
2.
Gupta R, Sharma A, Gupta R, Agarwal SK, Dinda AK. Morphometry of non-inflammatory arteriolar changes in lupus nephritis: a study of 40 cases. Saudi J Kidney Dis Transpl. 2012;23:1196–201.PubMed
3.
Das NK, Dutta RN, Sengupta SR. Skin lesions in lupus erythematosus: a marker of systemic involvement. Indian J Dermatol. 2011;56:537–40.PubMedCrossRef
4.
Benseler SM, Silverman ED. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus. 2007;16:564–71.PubMedCrossRef
5.
Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am. 2012;59:345–64.PubMedCrossRef
6.
Lee HS, Bae SC. What can we learn from genetic studies of systemic lupus erythematosus? Implications of genetic heterogeneity among populations in SLE. Lupus. 2010;19:1452–9.PubMedCrossRef
7.
Weckerle CE, Niewold TB. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol. 2011;40:42–9.PubMedCrossRef
8.
Martin MU, Wesche H. Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. Biochim Biophys Acta. 2002;1592:265–80.PubMedCrossRef
9.
Jacob CO, Reiff A, Armstrong DL, Myones BL, Silverman E, Klein-Gitelman M, et al. Identification of novel susceptibility genes in childhood-onset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform. Arthritis Rheum. 2007;56:4164–73.PubMedCrossRef
10.
Ringwood L, Li L. The involvement of the interleukin-1 receptor-associated kinases (IRAKs) in cellular signaling networks controlling inflammation. Cytokine. 2008;42:1–7.PubMedCrossRef
11.
12.
Gottipati S, Rao NL, Fung-Leung WP. IRAK1: a critical signaling mediator of innate immunity. Cell Signal. 2008;20:269–76.PubMedCrossRef
13.
Kollewe C, Mackensen AC, Neumann D, Knop J, Cao P, Li S, et al. Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J Biol Chem. 2004;279:5227–36.PubMedCrossRef
14.
Jacob CO, Zhu J, Armstrong DL, Yan M, Han J, Zhou XJ, et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci USA. 2009;106:6256–61.PubMedCrossRef
15.
Janssens S, Beyaert R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell. 2003;11:293–302.PubMedCrossRef
16.
17.
Thomas JA, Allen JL, Tsen M, Dubnicoff T, Danao J, Liao XC, et al. Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase. J Immunol. 1999;163:978–84.PubMed
18.
Dieudé P, Bouaziz M, Guedj M, Riemekasten G, Airò P, Müller M, et al. Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1 196Phe/532Ser haplotype. Arthritis Rheum. 2011;63:3979–87.PubMedCrossRef
19.
Zhang H, Pu J, Wang X, Shen L, Zhao G, Zhuang C, et al. IRAK1 rs3027898 C/A polymorphism is associated with risk of rheumatoid arthritis. Rheumatol Int. 2012;. doi:10.​1007/​s00296-012-2379-3.
20.
Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA. A polymorphism in the 3′-UTR of interleukin-1 receptor-associated kinase (IRAK1), a target gene of miR-146a, is associated with rheumatoid arthritis susceptibility. Jt Bone Spine. 2010;77:411–3.CrossRef
21.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.PubMedCrossRef
22.
Uematsu S, Sato S, Yamamoto M, Hirotani T, Kato H, Takeshita F, et al. Interleukin-1 receptor- associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and T LR9-mediated interferon-α induction. J Exp Med. 2005;201:915–23.PubMedCrossRef
23.
Wang D, Fasciano S, Li L. The interleukin-1 receptor associated kinase 1 contributes to the regulation of NFAT. Mol Immunol. 2008;45:3902–8.PubMedCrossRef
24.
Maitra U, Davis S, Reilly CM, Li L. Differential regulation of Foxp3 and IL-17 expression in CD4 T helper cells by IRAK-1. J Immunol. 2009;182:5763–9.PubMedCrossRef
25.
Thomas JA, Haudek SB, Koroglu T, Tsen MF, Bryant DD, White DJ, et al. IRAK1 deletion disrupts cardiac Toll/IL-1 signaling and protects against contractile dysfunction. Am J Physiol Heart Circ Physiol. 2003;285:H597–606.PubMed
26.
Lis J, Jarząb A, Witkowska D. Molecular mimicry in the etiology of autoimmune diseases. Postepy Hig Med Dosw. 2012;66:475–91.CrossRef
27.
Torres-Carrillo NM, Ruiz-Noa Y, Martínez-Bonilla GE, Leyva-Torres SD, Torres-Carrillo N, Palafox-Sánchez CA, et al. The +1858C/T PTPN22 gene polymorphism confers genetic susceptibility to rheumatoid arthritis in Mexican population from the Western Mexico. Immunol Lett. 2012;147:41–6.PubMedCrossRef
28.
Dieudé P, Guedj M, Wipff J, Avouac J, Hachulla E, Diot E. The PTPN22 620 W allele confers susceptibility to systemic sclerosis: findings of a large case–control study of European Caucasians and a meta-analysis. Arthritis Rheum. 2008;58:2183–8.PubMedCrossRef
29.
Lea WW, Lee YH. The association between the PTPN22 C1858T polymorphism and systemic lupus erythematosus: a meta-analysis update. Lupus. 2011;20:51–7.PubMedCrossRef
30.
Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA. The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. Scand J Immunol. 2010;71:382–5.PubMedCrossRef
31.
Liu G, Tsuruta Y, Gao Z, Park YJ, Abraham E. Variant IL-1 receptor-associated kinase-1 mediates increased NF-kappa B activity. J Immunol. 2007;179:4125–34.PubMed
Metadata
Title
Association of interleukin-1 receptor-associated kinase (IRAK1) gene polymorphisms (rs3027898, rs1059702) with systemic lupus erythematosus in a Chinese Han population
Authors
Yu Zhai
Ke Xu
Rui-Xue Leng
Han Cen
Wei Wang
Yan Zhu
Mo Zhou
Chen-Chen Feng
Dong-Qing Ye
Publication date
01-06-2013
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 6/2013
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-013-0607-2

Other articles of this Issue 6/2013

Inflammation Research 6/2013 Go to the issue

Original Research Paper

Concentration dependent anti-inflammatory effects thrombin on polyphosphate-mediated inflammatory responses in vitro and in vivo

Original Research Paper

Interleukin-22 produced by alveolar macrophages during activation of the innate immune response

Original Research Paper

Lipopeptides rather than lipopolysaccharide favor the development of dendritic cell dysfunction similar to polymicrobial sepsis in mice

Original Article

Suppression of Toll-like receptor 4 activation by endogenous oxidized phosphatidylcholine, KOdiA-PC by inhibiting LPS binding to MD2

Original Research Paper

Antagonism of the histamine H4 receptor reduces LPS-induced TNF production in vivo

Original Research Paper

Tumor necrosis factor-α, monocyte chemoattractant protein-1 and intercellular adhesion molecule-1 increase during the development of a 2,4-dinitrofluorobenzene-induced immediate-type dermatitis in rats
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits